63. Idiopathic thrombocytopenic purpura Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 391 Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

Drugs and their primary sponsors and trial info
10-mg dose of E5501 2G tablet   
   Eisai Inc.
      2012   Phase 1   NCT01549054   United Kingdom;
10-mg dose of E5501 cyclodextrin oral solution   
   Eisai Inc.
      2012   Phase 1   NCT01549054   United Kingdom;
10-mg dose of E5501 lipid-based oral   
   Eisai Inc.
      2012   Phase 1   NCT01549054   United Kingdom;
10-mg dose of E5501-P powder   
   Eisai Inc.
      2012   Phase 1   NCT01549054   United Kingdom;
AKR-501, YM-477   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000830-12-PL   Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-NL   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-CZ   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000830-12-GR   Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-SK   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BG   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BE   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
AMG 531   
   Amgen
      2007   Phase 3   NCT00603642   Japan;
      2007   Phase 1/Phase 2   NCT00515203   Australia;Canada;Spain;United States;
      2005   Phase 3   NCT00102336   United States;
      2005   Phase 3   NCT00102323   France;Netherlands;Spain;United States;
   Amgen Inc
      2013   Phase 2   EUCTR2010-019987-35-FR   Czech Republic;France;Germany;Italy;Spain;United Kingdom;
      2010   Phase 4   EUCTR2008-004347-10-BG   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2010   Phase 2   EUCTR2010-019987-35-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-DE   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-CZ   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2009   Phase 4   EUCTR2008-004347-10-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   Phase 4   EUCTR2008-004347-10-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SI   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
   Amgen Inc.
      2009   -   EUCTR2007-000638-37-IE   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2004-000172-13-GB   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
      2008   Phase 2   EUCTR2007-000638-37-SK   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-NL   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-GB   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-ES   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-CZ   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-BE   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-AT   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2004-000172-13-DE   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
      2008   -   EUCTR2004-000172-13-CZ   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
      2008   -   EUCTR2004-000172-13-BE   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
      2008   -   EUCTR2004-000172-13-AT   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
      2007   Phase 3   EUCTR2006-003700-18-GB   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   Phase 3   EUCTR2006-003700-18-FR   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   Phase 3   EUCTR2006-003700-18-BE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2007-003569-42-ES   Spain;
      2007   -   EUCTR2006-003700-18-PT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2006-003700-18-NL   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2006-003700-18-DE   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2006-003700-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
      2007   -   EUCTR2006-003700-18-AT   Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
AMG531   
   AMGEN S.P.A.
      2008   -   EUCTR2007-000638-37-IT   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2004-000172-13-IT   Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom;
ARGX-113   
   ARGENX BV
      2021   Phase 3   EUCTR2020-004033-20-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-IT   Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Argenx BVBA
      2019   Phase 2   EUCTR2019-000361-21-GB   Hungary;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
      2017   Phase 2   EUCTR2016-003038-26-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
   argenx
      2017   Phase 2   NCT03102593   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom;
   argenx BV
      2021   Phase 3   EUCTR2019-002101-21-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-BE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   argenx BVBA
      2020   Phase 3   EUCTR2019-002101-21-HU   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-BE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002100-41-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002100-41-HU   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002100-41-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Acetominofene   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Acetominophen   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Alemtuzumab, Rituximab   
   Hospital Universitario Dr. Jose E. Gonzalez
      2008   Phase 2/Phase 3   NCT00749112   Mexico;
All-Trans Retinoid Acid(ATRA)   
   Shandong University
      2013   Phase 3   NCT01882127   China;
Aminophylline   
   Department of Hematology, The First Affiliated Hospital of Soochow University
      2017   -   ChiCTR-ONC-17013230   China;
Amoxicillin hydrate   
   Takeda
      2015   -   NCT03219723   Japan;
Anti-CD40L   
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-001429-33-PL   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
      2014   Phase 2   EUCTR2014-001429-33-GB   Canada;Poland;United Kingdom;United States;
Anti-CD40LdAb   
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-001429-33-PL   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
      2014   Phase 2   EUCTR2014-001429-33-GB   Canada;Poland;United Kingdom;United States;
Anti-D   
   University of Aarhus
      2004   Phase 2   NCT00128882   Denmark;
Atorvastatin   
   Shandong University
      2021   Phase 2/Phase 3   NCT03692754   China;
Avatrombopag   
   Eisai Inc.
      2012   Phase 3   NCT01433978   United States;
   Institute of Hematology & Blood Diseases Hospital
      2021   -   NCT04890041   China;
   Shandong University
      2021   -   NCT04949009   China;
Avatrombopag (proposed)   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000830-12-PL   Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-NL   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-CZ   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   -   EUCTR2011-000830-12-GR   Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-SK   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BG   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BE   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
Avatrombopag maleate   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Avatrombopag tablets   
   Eisai Inc.
      2007   Phase 2   NCT00441090   United States;
Azathioprine   
   The Second Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000030603   China;
   the Second Affiliated Hospital of Kunming Medical University
      2019   -   ChiCTR1900027753   China;
BMS-986004   
   Bristol-Myers Squibb International Corporation
      2015   Phase 2   EUCTR2014-001429-33-PL   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States;
      2014   Phase 2   EUCTR2014-001429-33-GB   Canada;Poland;United Kingdom;United States;
BMS-986004 1500 mg IV   
   Bristol-Myers Squibb
      2014   Phase 1/Phase 2   NCT02273960   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 225 mg IV   
   Bristol-Myers Squibb
      2014   Phase 1/Phase 2   NCT02273960   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 675 mg IV   
   Bristol-Myers Squibb
      2014   Phase 1/Phase 2   NCT02273960   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BMS-986004 75 mg IV   
   Bristol-Myers Squibb
      2014   Phase 1/Phase 2   NCT02273960   Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States;
BT595   
   Biotest
      2016   Phase 3   NCT02859909   Bulgaria;Czechia;Germany;Hungary;Serbia;Spain;
   Biotest AG
      2018   Phase 3   EUCTR2015-003653-17-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-DE   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-BG   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-HU   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-ES   Bulgaria;Czech Republic;Germany;Hungary;Spain;
Blinded (Avatrombopoag tablets)   
   Eisai Inc.
      2007   Phase 2   NCT00625443   United States;
Blisibimod   
   Anthera Pharmaceuticals
      2015   Phase 2/Phase 3   NCT01609452   -
Bortezomib   
   Shandong University
      2018   Phase 3   NCT03443570   China;
Caffeic acid tablets   
   Shandong University
      2015   Phase 4   NCT02556814   China;
Clarithromycin   
   Takeda
      2015   -   NCT03219723   Japan;
Conventional   
   Nayera Hazaa Elsherif
      2018   -   NCT03412188   Egypt;
Corticosteroids (Aprednislon)   
   Ingrid Pabinger, MD
      2009   Phase 4   NCT00888901   Austria;
CsA   
   Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
      2016   -   ChiCTR-INR-16009363   China;
Cyclosporin A   
   Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
      2016   -   ChiCTR-INR-16009363   China;
   Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
      2018   -   ChiCTR-OON-17014165   China;
Cyclosporine   
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2022   Phase 4   ChiCTR2000040991   China;
   The Second Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000030603   China;
   the Second Affiliated Hospital of Kunming Medical University
      2019   -   ChiCTR1900027753   China;
DIFENIDRAMINA CLORIDRATO   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Danazol   
   Second Affiliated Hospital of Dalian Medical University
      2018   -   ChiCTR1800016177   China;
Decitabine   
   Shandong University
      2018   Phase 3   NCT03252457   China;
Dexamethasone   
   Cooperative Study Group A for Hematology
      2005   Phase 3   NCT00451594   Korea, Republic of;
   Department of Hematology, Anhui Provincial Hospital
      2020   Phase 4   ChiCTR1900027735   China;
   G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
      2008   -   EUCTR2008-000417-30-IT   Italy;
   Henan Cancer Hospital
      2020   Phase 4   ChiCTR2000035408   China;
   Hoffmann-La Roche
      2005   Phase 3   NCT00770562   Italy;
   Jinshan Hospital, Fudan University
      2020   Phase 4   ChiCTR2100045747   China;
   Nakayama Takayuki
      2019   Phase 1   JPRN-jRCTs041190069   Japan;
   Shandong University
      2021   Phase 2/Phase 3   NCT03692754   China;
      2021   Phase 2   NCT05023915   China;
      2019   Phase 4   NCT03998982   China;
      2018   Phase 3   NCT03252457   China;
      2015   Phase 4   NCT02556814   China;
      2013   Phase 3   NCT01882127   China;
      2012   Phase 3   NCT01734057   China;
      2012   Phase 3   NCT01734044   China;
      2010   Phase 4   NCT01356511   China;
   University Hospital, Macau
      2015   -   ChiCTR1900021211   China;
Dexamethasone (1 cycle)   
   Shandong University
      2015   Phase 4   NCT02642380   China;
Dexamethasone (4 cycles)   
   Shandong University
      2015   Phase 4   NCT02642380   China;
Dexamethasone Abcur   
   Sykehuset Østfold HF
      2016   Phase 3   EUCTR2015-005276-14-DK   Denmark;Egypt;France;Norway;Tunisia;
Dexamethasone and Rituximab   
   Copenhagen University Hospital at Herlev
      2004   Phase 3   NCT00909077   Denmark;
Diammonium glycyrrhizinate enteric-coated capsule   
   Shandong University
      2021   Phase 2   NCT05023915   China;
Doptelet 20 mg film-coated tablets   
   Dova Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2020-003232-24-DE   Czechia;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003232-24-FR   Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
   Sobi, Inc.
      2020   Phase 3   EUCTR2020-003232-24-PL   France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003232-24-HU   France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States;
Doxil   
   Hematology and Oncology Specialists
      2001   Phase 2   NCT00107913   United States;
Dyphenhydramine hydrochloride   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
E5501   
   Eisai Inc.
      2011   Phase 1   NCT01437384   United States;
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000830-12-PL   Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-NL   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   Phase 3   EUCTR2011-000830-12-CZ   Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000830-12-GR   Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-SK   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BG   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
      2011   Phase 3   EUCTR2011-000830-12-BE   Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine;
E5501 40 mg 2 x 20-mg tablets, orally, fasted   
   Eisai Inc.
      2011   Phase 1   NCT01327872   Netherlands;
E5501 40 mg 2 x 20-mg tablets, orally, with food   
   Eisai Inc.
      2011   Phase 1   NCT01327872   Netherlands;
E5501 40mg 2 x 20-mg tablets, orally, fasted   
   Eisai Inc.
      2011   Phase 1   NCT01327872   Netherlands;
ELTROMBOPAG OLAMINE   
   Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
      2015   Phase 2   EUCTR2015-001327-23-IT   Italy;
Efgartigimod   
   ARGENX BV
      2020   Phase 3   EUCTR2019-002101-21-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-IT   Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   Argenx BVBA
      2019   Phase 2   EUCTR2019-000361-21-GB   Hungary;Spain;Ukraine;United Kingdom;
   argenx
      2020   Phase 3   NCT04274452   United States;
      2020   Phase 3   NCT04225156   Austria;Belgium;Bulgaria;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT04188379   Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   argenx BV
      2020   Phase 3   EUCTR2019-002101-21-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-BE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
   argenx BVBA
      2020   Phase 3   EUCTR2019-002101-21-HU   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC   
   ARGENX BV
      2021   Phase 3   EUCTR2020-004033-20-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
   argenx
      2021   Phase 3   NCT04812925   Australia;Japan;Russian Federation;United States;
      2020   Phase 3   NCT04687072   Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
   argenx BV
      2022   Phase 3   EUCTR2020-004032-21-DK   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-PT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-NO   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-GR   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-ES   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-BG   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-PT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-NO   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-IE   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-DE   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-BG   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004032-21-GR   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
Efgartigimod alfa   
   ARGENX BV
      2021   Phase 3   EUCTR2020-004033-20-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-IT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
   Gandini Domenica
      2021   Phase 3   JPRN-jRCT2071210025   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United State;
   argenx BV
      2022   Phase 3   EUCTR2020-004032-21-DK   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-PT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-NO   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-GR   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-ES   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004033-20-BG   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-PT   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-NO   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-IE   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-DE   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004032-21-BG   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004032-21-GR   Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States;
   argenx BVBA
      2020   Phase 3   EUCTR2019-002101-21-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002101-21-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-BE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-002100-41-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alpha   
   argenx BVBA
      2020   Phase 3   EUCTR2019-002100-41-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002100-41-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
Eltrombopag   
   Eisai Inc.
      2012   Phase 3   NCT01433978   United States;
   GLAXOSMITHKLINE R&D LTD
      2007   -   EUCTR2006-000471-14-IT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
   GlaxoSmithKline
      2012   Phase 3   NCT01520909   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2009   Phase 2   NCT00908037   Canada;France;Netherlands;Spain;United Kingdom;United States;
      2007   Phase 2   NCT00424177   Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States;
      2006   Phase 3   NCT00370331   Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2006-002946-13-NL   France;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2006-002946-13-GB   France;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2006-002946-13-FR   France;Netherlands;Spain;United Kingdom;
      -   -   EUCTR2006-002946-13-Outside-EU/EEA   Canada;United States;
   GlaxoSmithKline Research and Development Limited
      2008   Phase 4   EUCTR2006-000471-14-IE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000471-14-SK   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
      2007   Phase 3   EUCTR2006-000471-14-DK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000471-14-DE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000470-78-SK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-002943-10-GB   Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-002943-10-DE   Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-000471-14-GR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-FI   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-AT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000470-78-IT   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-000470-78-GR   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-000470-78-DE   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-000470-78-CZ   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000471-14-SE   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
      2006   Phase 3   EUCTR2006-000471-14-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-000471-14-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2006-000471-14-SI   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000471-14-NL   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000470-78-NL   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-FI   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-DK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-AT   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline S.A.
      2009   Phase 2   EUCTR2006-002946-13-ES   France;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2007   Phase 2   EUCTR2006-002943-10-ES   Germany;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-ES   Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
   Gruppo Italiano Malattie EMatologiche dell'Adulto
      2016   Phase 2   NCT02402998   Italy;
      2016   -   NCT02298075   Italy;
   Humanity & Health Medical Group Limited
      2018   Phase 2   NCT03830749   Hong Kong;
   Ingrid Pabinger, MD
      2009   Phase 4   NCT00888901   Austria;
   Nayera Hazaa Elsherif
      2018   -   NCT03412188   Egypt;
   Novartis Pharmaceuticals
      2010   -   NCT01416311   -
   Peking University People's Hospital
      2020   -   NCT04214951   China;
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2022   Phase 4   ChiCTR2000040991   China;
   The Second Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000030603   China;
   University Hospital, Macau
      2015   -   ChiCTR1900021211   China;
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00902018   United States;
   Wuhan Union Hospital, China
      2019   Phase 4   NCT03771378   China;
Eltrombopag (Revolade)   
   GlaxoSmithKline Research & Development Limited
      2010   Phase 4   EUCTR2009-010421-39-FR   Czech Republic;France;Germany;Hungary;Italy;
Eltrombopag (Revolade®)   
   University Children's Hospital Basel
      2022   Phase 2   NCT04812483   Switzerland;
Eltrombopag combining rituximab   
   Institute of Hematology & Blood Diseases Hospital
      2020   Phase 4   NCT04518475   China;
Eltrombopag olamine (SB-497115-GR)   
   Novartis Pharmaceuticals
      2006   Phase 3   NCT00351468   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
Eltrombopag olamine, Revolade, Promacta   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Eltrombopag oral tablets   
   GlaxoSmithKline
      2008   Phase 3   NCT00828750   Japan;
Eltrombopag plus diacerein   
   Qilu Hospital of Shandong University
      2020   Phase 2   NCT04917679   China;
FCM   
   Shandong University
      2016   -   NCT02967328   China;
GMA161   
   Genzyme, a Sanofi Company
      2005   Phase 1   NCT00244257   United States;
GNR-069   
   AO GENERIUM
      2021   Phase 3   NCT05220878   Russian Federation;
Gammaplex   
   Bio Products Laboratory Limited
      -   -   EUCTR2011-005586-21-Outside-EU/EEA   Argentina;India;United States;
Gammaplex, intravenous immunoglobulin   
   Bio Products Laboratory
      2007   Phase 3   NCT00504075   Argentina;India;United States;
Glycyrrhetinic Acid   
   Shandong University
      2019   Phase 4   NCT03998982   China;
HBM9161 Dose A   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2020   Phase 2/Phase 3   NCT04428255   China;
HBM9161 Dose B   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2020   Phase 2/Phase 3   NCT04428255   China;
HMPL-523   
   Hutchison Medipharma Limited
      2021   Phase 3   NCT05029635   -
HUMAN NORMAL IMMUNOGLOBULIN (IV)   
   Biotest AG
      2018   Phase 3   EUCTR2015-003653-17-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-DE   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-BG   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-HU   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-ES   Bulgaria;Czech Republic;Germany;Hungary;Spain;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE   
   LFB BIOTECHNOLOGIES
      2012   Phase 3   EUCTR2011-001354-29-ES   Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-HU   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-DE   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE   
   LFB BIOTECHNOLOGIES
      2012   Phase 3   EUCTR2011-001354-29-ES   Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-HU   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-DE   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
HUMAX-CD38   
   Ostfold Hospital Trust
      2020   Phase 2   EUCTR2019-004683-22-NO   Norway;
Hetrombopag   
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 3   NCT04737850   China;
Hetrombopag Olamine   
   Jiangsu HengRui Medicine Co., Ltd.
      2017   Phase 3   NCT03222843   China;
      2015   Phase 1   NCT02614846   China;
      2014   Phase 1   NCT02403440   China;
High dose Dexamethasone pulses   
   Isfahan University of Medical Sciences
      2016   Phase 2/Phase 3   NCT02914054   Iran, Islamic Republic of;
Huaiqihuang Granule   
   Qidong Gaitianli Medicines Co., Ltd
      2017   Phase 4   NCT03201848   China;
Human Immunoglobulin   
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2011-001354-29-DE   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
   Octapharma AG
      2007   Phase 3   EUCTR2005-003552-35-FR   Austria;Czech Republic;France;Germany;
Human Normal Immunoglobulin (iv)   
   Biotest AG
      2018   Phase 3   EUCTR2015-003653-17-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-DE   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-BG   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-HU   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-ES   Bulgaria;Czech Republic;Germany;Hungary;Spain;
Human Normal Immunoglobulin G (IgG > purity)   
   CSL Behring GmbH
      2011   -   EUCTR2011-000263-27-BG   Bulgaria;Poland;Serbia;Turkey;
   CSL Behring LLC
      2011   -   EUCTR2011-000263-27-PL   Bulgaria;Poland;Serbia;Turkey;
Human normal immunoglobulin   
   OCTAPHARMA AG
      2012   -   EUCTR2012-000796-16-PL   Bulgaria;Czech Republic;Poland;
      2012   -   EUCTR2012-000796-16-DE   Bulgaria;Czech Republic;Germany;Poland;
      2012   -   EUCTR2012-000796-16-BG   Bulgaria;Czech Republic;Poland;
Human normal immunoglobulin for intravenous use   
   LFB BIOTECHNOLOGIES
      2011   -   EUCTR2011-001354-29-IT   Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
Hydroxychloroquine   
   Jinshan Hospital, Fudan University
      2020   Phase 4   ChiCTR2100045747   China;
I10E   
   LFB BIOTECHNOLOGIES
      2012   Phase 3   EUCTR2011-001354-29-ES   Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-IT   Germany;Hungary;Italy;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-HU   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2011   -   EUCTR2011-001354-29-DE   France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
IGIV3I Grifols   
   Grifols Biologicals Inc.
      2008   Phase 3   NCT00511147   Canada;India;Puerto Rico;United States;
IMMUNOGLOBULIN G   
   OCTAPHARMA AG
      2012   -   EUCTR2012-000796-16-PL   Bulgaria;Czech Republic;Poland;
      2012   -   EUCTR2012-000796-16-DE   Bulgaria;Czech Republic;Germany;Poland;
      2012   -   EUCTR2012-000796-16-CZ   Bulgaria;Czech Republic;Germany;Poland;
      2012   -   EUCTR2012-000796-16-BG   Bulgaria;Czech Republic;Poland;
   Octapharma AG
      2013   -   EUCTR2009-014589-24-FR   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2012   -   EUCTR2009-014589-24-BG   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2011   -   EUCTR2009-014589-24-DE   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2011   -   EUCTR2009-014589-24-CZ   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
IVIG-L   
   Sanquin
      2001   Phase 3   NCT00151840   Poland;
Ig VENA 100 ml vial   
   Kedrion SpA
      2013   -   EUCTR2013-000961-36-IT   Italy;
Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set   
   Kedrion SpA
      2013   Phase 3   EUCTR2013-000961-36-DE   Germany;Italy;
IgG Next Generation   
   Biotest AG
      2018   Phase 3   EUCTR2015-003653-17-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-DE   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2017   Phase 3   EUCTR2015-003653-17-BG   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-HU   Bulgaria;Czech Republic;Germany;Hungary;Spain;
      2016   Phase 3   EUCTR2015-003653-17-ES   Bulgaria;Czech Republic;Germany;Hungary;Spain;
IgNextGen   
   CSL Limited
      2007   Phase 3   NCT00362349   Australia;
Immune Globulin Intravenous (Human), Triple Virally Reduced Solution   
   Baxalta now part of Shire
      2003   Phase 2   NCT00162006   Czech Republic;Czechia;Germany;Hungary;Poland;
Immunglobulin   
   Octapharma AG
      2011   -   EUCTR2009-014589-24-DE   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
Inactivated Trivalent Influenza vaccine   
   Neufeld, Ellis J, MD, PhD
      2004   -   NCT01713855   United States;
LIV-GAMMA SN Inj.   
   SK Plasma Co., Ltd.
      2016   Phase 3   NCT03164915   Korea, Republic of;
Lansoprazole, clarithromycin, amoxycillin   
   Mahidol University
      2006   Phase 4   NCT00467571   Thailand;
MabThera   
   Rikshospitalet
      2008   -   EUCTR2005-005918-20-FR   France;Sweden;United Kingdom;
Medical Standard of Care for ITP   
   Amgen
      2006   Phase 3   NCT00415532   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Methylprednisolone   
   Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
      2016   Phase 4 study   ChiCTR-IIR-16008994   China;
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
Metronidazole   
   Takeda
      2015   -   NCT03219723   Japan;
Montelukast   
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039630   China;
NPLATE 500 microgramos polvo para solución inyectable   
   Amgen Inc
      2010   Phase 2   EUCTR2010-019987-35-ES   Czech Republic;France;Germany;Italy;Spain;United Kingdom;
Nanogam   
   University Medical Center Utrecht
      2009   Phase 3   EUCTR2008-001597-33-NL   Netherlands;
NewGAM   
   Octapharma AG
      2013   -   EUCTR2009-014589-24-FR   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2012   -   EUCTR2009-014589-24-BG   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2011   -   EUCTR2009-014589-24-DE   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
      2011   -   EUCTR2009-014589-24-CZ   Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine;
NewGam   
   Octapharma
      2011   Phase 3   NCT01349790   Germany;
Nplate   
   AO GENERIUM
      2021   Phase 3   NCT05220878   Russian Federation;
   Amgen Inc
      2013   Phase 2   EUCTR2010-019987-35-FR   Czech Republic;France;Germany;Italy;Spain;United Kingdom;
      2010   Phase 4   EUCTR2008-004347-10-BG   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2010   Phase 2   EUCTR2010-019987-35-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-DE   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-CZ   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2009   Phase 4   EUCTR2008-004347-10-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   Phase 4   EUCTR2008-004347-10-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SI   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
Octagam   
   OCTAPHARMA AG
      2012   -   EUCTR2012-000796-16-PL   Bulgaria;Czech Republic;Poland;
      2012   -   EUCTR2012-000796-16-DE   Bulgaria;Czech Republic;Germany;Poland;
      2012   -   EUCTR2012-000796-16-CZ   Bulgaria;Czech Republic;Germany;Poland;
      2012   -   EUCTR2012-000796-16-BG   Bulgaria;Czech Republic;Poland;
   Octapharma
      2006   Phase 3   NCT00426270   Austria;
   Octapharma AG
      2006   -   EUCTR2005-003552-35-CZ   Czech Republic;France;Germany;
Octagam®   
   Octapharma AG
      2007   Phase 3   EUCTR2005-003552-35-FR   Austria;Czech Republic;France;Germany;
      2006   -   EUCTR2005-003552-35-DE   Czech Republic;France;Germany;
      2006   -   EUCTR2005-003552-35-AT   Austria;Czech Republic;France;Germany;
Open Label (Avatrombopag tablets)   
   Eisai Inc.
      2007   Phase 2   NCT00625443   United States;
Orelabrutinib   
   Shandong University
      2021   Phase 2   NCT05020288   -
Orelabrutinib( higher dose)   
   Beijing InnoCare Pharma Tech Co., Ltd.
      2022   Phase 2   NCT05232149   China;
Orelabrutinib( lower dose)   
   Beijing InnoCare Pharma Tech Co., Ltd.
      2022   Phase 2   NCT05232149   China;
PF-06755347 intravenous healthy participant   
   Pfizer
      2017   Phase 1   NCT03275740   Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous ITP   
   Pfizer
      2017   Phase 1   NCT03275740   Belgium;New Zealand;United Kingdom;United States;
PF-06755347 subcutaneous healthy participant   
   Pfizer
      2017   Phase 1   NCT03275740   Belgium;New Zealand;United Kingdom;United States;
PF-06835375   
   Pfizer
      2022   Phase 2   NCT05070845   Poland;United States;
   Pfizer Inc.
      2022   Phase 2   EUCTR2021-002897-19-HU   Australia;Canada;Czechia;Hungary;Poland;United States;
PG2   
   PhytoHealth Corporation
      2008   Phase 2   NCT00860600   Taiwan;
PRTX-100 (Staphylococcal protein A)   
   Protalex, Inc.
      2007   Phase 1   NCT00571467   Australia;New Zealand;
Palmitate   
   Nakayama Takayuki
      2019   Phase 1   JPRN-jRCTs041190069   Japan;
Placebo   
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205351   Japan, Asia except Japan, North America, Europe;
Prednisolone   
   Cooperative Study Group A for Hematology
      2005   Phase 3   NCT00451594   Korea, Republic of;
Prednisone   
   Department of Hematology, Anhui Provincial Hospital
      2020   Phase 4   ChiCTR1900027735   China;
   G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
      2008   -   EUCTR2008-000417-30-IT   Italy;
   Isfahan University of Medical Sciences
      2016   Phase 2/Phase 3   NCT02914054   Iran, Islamic Republic of;
   Shandong University
      2010   Phase 4   NCT01356511   China;
Privigen®   
   CSL Behring GmbH
      2011   -   EUCTR2011-000263-27-BG   Bulgaria;Poland;Serbia;Turkey;
   CSL Behring LLC
      2011   -   EUCTR2011-000263-27-PL   Bulgaria;Poland;Serbia;Turkey;
Proteína recombinante estimulante de la megacariopoyesis   
   Amgen Inc.
      2007   -   EUCTR2007-003569-42-ES   Spain;
R788   
   Kissei Pharmaceutical Co., Ltd.
      2019   Phase 3   NCT04132050   Japan;
REVOLADE, PROMACTA   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-002184-17-IT   Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      -   -   EUCTR2006-002946-13-Outside-EU/EEA   Canada;United States;
   Glaxosmithkline Research and Development Ltd
      2012   Phase 3   EUCTR2011-002184-17-GB   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002184-17-CZ   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   -   EUCTR2011-002184-17-PL   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   -   EUCTR2011-002184-17-DE   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
   Glaxosmithkline, S.A.
      2012   Phase 3   EUCTR2011-002184-17-ES   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
Recombinant Human Thrombopoietin   
   Department of Hematology, Anhui Provincial Hospital
      2020   Phase 4   ChiCTR1900027735   China;
Recombinant Human Thrombopoietin (rhTPO)   
   Shandong University
      2014   Phase 3   NCT02139501   China;
Recombinant human thrombopoietin (rh-TPO)   
   Peking University People's Hospital
      2020   -   NCT04214951   China;
Recombinant human thrombopoietin (rhTPO)   
   Shandong University
      2012   Phase 3   NCT01734057   China;
      2012   Phase 3   NCT01734044   China;
      2011   Phase 3   NCT01525836   China;
Relovade   
   GlaxoSmithKline Research and Development Ltd
      2013   -   EUCTR2013-001371-20-BE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
   GlaxoSmithKline, S.A.
      2013   Phase 4   EUCTR2013-001371-20-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade   
   Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
      2015   Phase 2   EUCTR2015-001327-23-IT   Italy;
   GlaxoSmithKline
      2010   -   EUCTR2009-010421-39-HU   Czech Republic;France;Germany;Hungary;Italy;
      2010   -   EUCTR2009-010421-39-DE   Czech Republic;France;Germany;Hungary;Italy;
      2010   -   EUCTR2009-010421-39-CZ   Czech Republic;France;Germany;Hungary;Italy;
   GlaxoSmithKline Research and Development Limited
      2007   Phase 3   EUCTR2006-000471-14-SK   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
      2006   Phase 3   EUCTR2006-000471-14-SE   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
   GlaxoSmithKline Research and Development Ltd
      2014   -   EUCTR2013-001371-20-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2014   -   EUCTR2013-001371-20-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2013   -   EUCTR2013-001371-20-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2013   -   EUCTR2013-001371-20-BE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
Revolade 25 mg film-coated tablets   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Revolade 50 mg film-coated tablets   
   Eisai Limited
      2012   Phase 3   EUCTR2011-000831-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-NL   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-GB   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-ES   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-DE   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2012   -   EUCTR2011-000831-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
RhTPO   
   Department of Hematology, Anhui Provincial Hospital
      2020   Phase 4   ChiCTR1900027735   China;
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039630   China;
   Peking Union Medical College
      2011   Phase 3   NCT01805648   China;
   Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
      2016   -   ChiCTR-INR-16009363   China;
   Wuhan Union Hospital, China
      2019   Phase 4   NCT03771378   China;
RhTPO in combination with Rituximab   
   Ming Hou
      2009   Phase 3   NCT01506414   China;
Rituximab   
   Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
      2019   Phase 4   ChiCTR1900027748   China;
   Henan Cancer Hospital
      2020   Phase 4   ChiCTR2000035408   China;
   Hoffmann-La Roche
      2005   Phase 3   NCT00770562   Italy;
   Keio University School of Medicine , Yoshitaka miyakawa
      2011   Phase 3   JPRN-JMA-IIA00070   Japan;
   Neufeld, Ellis J, MD, PhD
      2003   Phase 1/Phase 2   NCT01713738   United States;
   ROCHE
      2005   -   EUCTR2005-000859-15-IT   Italy;
   Shandong University
      2018   Phase 3   NCT03443570   China;
      2012   Phase 3   NCT01734057   China;
      2011   Phase 3   NCT01525836   China;
      2010   Phase 4   NCT03258866   China;
   Sykehuset Østfold HF
      2016   Phase 3   EUCTR2015-005276-14-DK   Denmark;Egypt;France;Norway;Tunisia;
   The Second Affiliated Hospital of Kunming Medical University
      2020   Phase 4   ChiCTR2000030603   China;
   Weill Medical College of Cornell University
      2004   Phase 2   NCT00161564   United States;
Rituximab [MabThera/Rituxan]   
   Hoffmann-La Roche
      2007   Phase 2   NCT00475423   Australia;
Romiplostim   
   Amgen
      2012   Phase 3   NCT01444417   Australia;Canada;United States;
      2010   Phase 2   NCT01143038   Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2009   Phase 4   NCT00907478   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States;
      2009   Phase 3   NCT01071954   Australia;Canada;Spain;United States;
      2006   Phase 3   NCT00415532   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2005   Phase 3   NCT00508820   Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2004   Phase 3   NCT00116688   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2002   Phase 2   NCT00111475   -
   Amgen Inc
      2013   Phase 2   EUCTR2010-019987-35-FR   Czech Republic;France;Germany;Italy;Spain;United Kingdom;
      2010   Phase 4   EUCTR2008-004347-10-BG   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2010   Phase 2   EUCTR2010-019987-35-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-DE   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2010   -   EUCTR2010-019987-35-CZ   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2009   Phase 4   EUCTR2008-004347-10-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   Phase 4   EUCTR2008-004347-10-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SI   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-SE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-004347-10-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden;
   Amgen Inc.
      2008   Phase 2   EUCTR2007-000638-37-SK   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-NL   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-GB   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-ES   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-CZ   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-BE   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-000638-37-AT   Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.
      2015   Phase 3   NCT02868099   China;
   University Hospital, Basel, Switzerland
      2016   Phase 4   NCT02760251   Switzerland;
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00902018   United States;
Romiplostin   
   Gruppo Italiano Malattie EMatologiche dell'Adulto
      2016   -   NCT02298075   Italy;
Rozanolixizumab   
   Sugihara Kazuhiro
      2021   Phase 3   JPRN-jRCT2031210245   Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Poland;Republic of Moldova;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   UCB Biopharma SRL
      2020   Phase 3   NCT04596995   Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;
      2020   Phase 3   NCT04224688   Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04200456   Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-HU   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-GB   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-CZ   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205351   Japan, Asia except Japan, North America, Europe;
SB-497115   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-002184-17-IT   Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2006-002946-13-NL   France;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2006-002946-13-GB   France;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2006-002946-13-FR   France;Netherlands;Spain;United Kingdom;
      -   -   EUCTR2006-002946-13-Outside-EU/EEA   Canada;United States;
   GlaxoSmithKline Research and Development Ltd
      2014   -   EUCTR2013-001371-20-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2014   -   EUCTR2013-001371-20-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2013   Phase 4   EUCTR2013-001371-20-IE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2013   -   EUCTR2013-001371-20-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
      2013   -   EUCTR2013-001371-20-BE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
   GlaxoSmithKline S.A.
      2009   Phase 2   EUCTR2006-002946-13-ES   France;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2013   Phase 4   EUCTR2013-001371-20-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States;
   Glaxosmithkline Research and Development Ltd
      2012   Phase 3   EUCTR2011-002184-17-GB   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002184-17-CZ   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   -   EUCTR2011-002184-17-PL   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
      2012   -   EUCTR2011-002184-17-DE   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
   Glaxosmithkline, S.A.
      2012   Phase 3   EUCTR2011-002184-17-ES   Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States;
SB-497115-GR   
   GLAXOSMITHKLINE R&D LTD
      2007   -   EUCTR2006-000471-14-IT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
   GlaxoSmithKline
      2007   Phase 3   NCT00540423   Japan;
   GlaxoSmithKline Research and Development Limited
      2007   -   EUCTR2006-000470-78-IT   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
SB497115   
   GlaxoSmithKline
      2010   -   EUCTR2009-010421-39-HU   Czech Republic;France;Germany;Hungary;Italy;
      2010   -   EUCTR2009-010421-39-DE   Czech Republic;France;Germany;Hungary;Italy;
      2010   -   EUCTR2009-010421-39-CZ   Czech Republic;France;Germany;Hungary;Italy;
   GlaxoSmithKline Research & Development Limited
      2010   Phase 4   EUCTR2009-010421-39-FR   Czech Republic;France;Germany;Hungary;Italy;
   GlaxoSmithKline Research and Development Limited
      2008   Phase 4   EUCTR2006-000471-14-IE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000471-14-SK   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
      2007   Phase 3   EUCTR2006-000471-14-DK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000471-14-DE   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-000470-78-SK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-002943-10-GB   Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-002943-10-DE   Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-000471-14-GR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-FI   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-CZ   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000471-14-AT   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-000470-78-GR   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-000470-78-DE   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-000470-78-CZ   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000471-14-SE   Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam;
      2006   Phase 3   EUCTR2006-000471-14-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-000471-14-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-GB   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-FR   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2006   -   EUCTR2006-000471-14-SI   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000471-14-NL   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000470-78-NL   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-FI   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-DK   Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-000470-78-AT   Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2007   Phase 2   EUCTR2006-002943-10-ES   Germany;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000470-78-ES   Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam;
SM101   
   SuppreMol GmbH
      2010   Phase 1;Phase 2   EUCTR2009-014842-28-BE   Belgium;Germany;Poland;
SM101 20mg/mL   
   SuppreMol GmbH
      2010   -   EUCTR2009-014842-28-PL   Belgium;Germany;Poland;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014842-28-DE   Belgium;Germany;Poland;Russian Federation;Ukraine;
SM101 5mg/mL   
   SuppreMol GmbH
      2010   -   EUCTR2009-014842-28-PL   Belgium;Germany;Poland;Russian Federation;Ukraine;
      2010   -   EUCTR2009-014842-28-DE   Belgium;Germany;Poland;Russian Federation;Ukraine;
Sirolimus   
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States;
   Department of Hematology, Xiniao Hospital
      2017   -   ChiCTR-ONC-17012126   China;
Standard of care   
   Eisai Inc.
      2012   Phase 3   NCT01433978   United States;
Standard therapy (without eltrombopag): HD-DXM   
   University Children's Hospital Basel
      2022   Phase 2   NCT04812483   Switzerland;
Steroids   
   Safaa AA Khaled
      2019   -   NCT04113915   -
TAK-079   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-004103-12-IT   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
   Millennium Pharmaceuticals, Inc. (Takeda)
      2020   Phase 2   EUCTR2019-004103-12-SI   Bulgaria;Croatia;Germany;Slovenia;Ukraine;United States;
      2020   Phase 2   EUCTR2019-004103-12-HR   Croatia;Slovenia;Ukraine;United States;
   Takeda
      2020   Phase 2   NCT04278924   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
   Takeda Development Center Americas, Inc. (Takeda)
      2021   Phase 2   EUCTR2019-004103-12-DE   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
      2020   Phase 2   EUCTR2019-004103-12-BG   Bulgaria;Croatia;Germany;Italy;Slovenia;Ukraine;United States;
TPO   
   Shenyang Sunshine Pharmaceutical Co., LTD.
      2016   Phase 4   NCT04089267   China;
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication)   
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2015   -   JPRN-JapicCTI-153003   -
Triple therapy   
   Safaa AA Khaled
      2019   -   NCT04113915   -
Tysabri   
   Sahlgrenska University Hospital
      2009   -   EUCTR2008-005871-92-SE   Sweden;
UCB7665   
   UCB Biopharma S.P.R.L.
      2016   Phase 2   NCT02718716   Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
   UCB Biopharma SPRL
      2017   Phase 2   EUCTR2015-003984-12-LT   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2017   Phase 2   EUCTR2015-003984-12-BG   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2015-003984-12-PL   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2015-003984-12-ES   Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2015-003984-12-DE   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2015-003984-12-CZ   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
      2016   Phase 2   EUCTR2015-003984-12-BE   Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
   UCB Biopharma SRL
      2021   Phase 3   EUCTR2019-003451-11-DK   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-000884-26-HR   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-000884-26-GR   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-000883-40-DE   Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-IT   Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-FR   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-ES   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-DE   Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-CZ   Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003451-11-AT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-PL   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-NL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-IT   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-HU   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-GB   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-FR   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-ES   Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-CZ   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-BG   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000884-26-AT   Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-PL   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-HU   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-GB   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-CZ   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000883-40-BG   Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003984-12-IT   Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom;
Vonoprazan   
   Takeda
      2015   -   NCT03219723   Japan;
Water   
   Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
      2016   -   ChiCTR-INR-16009363   China;